← 返回

双吲哚衍生的 NR4A1 拮抗剂抑制结肠肿瘤和脾脏生长及 T 细胞耗竭

英文原题:Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion.

查看英文原题

Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion.

PubMed 2023/10/17(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

已有证据表明,孤儿核受体4A1(NR4A1,又称Nur77)在耗竭CD8+ T细胞中高表达,并调节肿瘤PD-L1。本研究考察强效双吲哚类NR4A1拮抗剂能否逆转T细胞耗竭并降低结肠肿瘤/细胞中的PD-L1。NR4A1拮抗剂可抑制小鼠MC-38来源结肠肿瘤及细胞生长,并下调PD-L1表达。MC-38结肠肿瘤的TIL和脾淋巴细胞均高表达PD-1、2B4、TIM3和TIGIT等T细胞耗竭标志物;脾脏中也观察到类似结果,而NR4A1拮抗剂可抑制这些标志物。对NR4A1拮抗剂处理后来源于TIL的CD8+ T细胞分析发现,干扰素、颗粒酶B和穿孔素mRNA等细胞因子活化标志物增加,TOX、TOX2和NFAT减少。因此,NR4A1拮抗剂既可降低结肠肿瘤中的NR4A1依赖性促癌活性和PD-L1表达,也能抑制TIL及脾脏中NR4A1依赖的T细胞耗竭,代表一种基于作用机制、可增强肿瘤免疫监视的新型药物类别。

展开英文摘要原文

There is evidence that the orphan nuclear receptor 4A1 (NR4A1, Nur77) is overexpressed in exhausted CD8 + T cells and regulates PD-L1 in tumors.

This study investigated the effects of potent bis-indole-derived NR4A1 antagonists on reversing T-cell exhaustion and downregulating PD-L1 in colon tumors/cells. NR4A1 antagonists inhibited colon tumor growth and downregulated expression of PD-L1 in mouse colon MC-38-derived tumors and cells. TILs from MC-38 cell-derived colon tumors and splenic lymphocytes exhibited high levels of the T-cell exhaustion markers including PD-1, 2B4, TIM3+ and TIGIT and similar results were observed in the spleen, and these were inhibited by NR4A1 antagonists.

In addition, treatment with NR4A1 antagonists induced cytokine activation markers interferon , granzyme B and perforin mRNAs and decreased TOX, TOX2 and NFAT in TIL-derived CD8 + T cells.

Thus, NR4A1 antagonists decrease NR4A1-dependent pro-oncogenic activity and PD-L1 expression in colon tumors and inhibit NR4A1-dependent T-cell exhaustion in TILs and spleen and represent a novel class of mechanism-based drugs that enhance immune surveillance in tumors.

论文信息

作者
Mohankumar K、Wright G、Kumaravel S、Shrestha R、Zhang L、Abdelrahim M、Chapkin RS、Safe S
第一作者单位
Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, 77843, USA.United States
通讯作者单位
Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, 77843, USA. ssafe@cvm.tamu.edu.United States
期刊
Cancer immunology, immunotherapy : CII2023 Dec
原文标识
PubMed 37847301 · DOI 10.1007/s00262-023-03530-3